Gelonghui, March 21丨Lisheng Pharmaceutical (002393.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1.153 billion yuan, up 0.56% year on year; net profit attributable to shareholders of listed companies was 362 million yuan, up 286.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149.6 million yuan, up 20.26% year on year; basic income per share was 1.97 yuan; it plans to distribute a cash dividend of 6.00 yuan (tax included) for every 10 shares to all shareholders, using capital reserves to all shareholders 10 shares were transferred to 4 shares.
力生制药(002393.SZ)：2023年度净利润增286.54%至3.62亿元 拟10转4派6元
Lisheng Pharmaceutical (002393.SZ): Net profit increased by 286.54% to 362 million yuan in 2023, plans to convert 10 to 4 to 6 yuan
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.